Skip to Main Content
Table 1—

Baseline characteristics of study patients

Baseline characteristicsLosartan groupPlacebo group
n 10 10 
Sex (M/F) 10/0 9/1 
Age (years) 60.6 ± 3.7 63.1 ± 3.9 
Duration of diabetes (years)* 8.5 (1–38) 4.0 (1–10) 
BMI (kg/m230.4 ± 2.1 28.1 ± 1.6 
Serum creatinine (mmol/l) 97 ± 6.5 92 ± 2.7 
24-h urine sodium (mmol/24hr) 230 ± 36 210 ± 26 
Clinic mean arterial blood pressure (mmHg) 114 ± 3 111 ± 3 
AER (μg/min) 26.6 ± 1.4 32.6 ± 1.3 
HbA1c (%) 7.9 ± 0.5 7.4 ± 0.4 
Diabetes treatment   
 Diet alone 
 Metformin ± sulphonylurea 
 Thiazolidinedione 
 Insulin 
Baseline characteristicsLosartan groupPlacebo group
n 10 10 
Sex (M/F) 10/0 9/1 
Age (years) 60.6 ± 3.7 63.1 ± 3.9 
Duration of diabetes (years)* 8.5 (1–38) 4.0 (1–10) 
BMI (kg/m230.4 ± 2.1 28.1 ± 1.6 
Serum creatinine (mmol/l) 97 ± 6.5 92 ± 2.7 
24-h urine sodium (mmol/24hr) 230 ± 36 210 ± 26 
Clinic mean arterial blood pressure (mmHg) 114 ± 3 111 ± 3 
AER (μg/min) 26.6 ± 1.4 32.6 ± 1.3 
HbA1c (%) 7.9 ± 0.5 7.4 ± 0.4 
Diabetes treatment   
 Diet alone 
 Metformin ± sulphonylurea 
 Thiazolidinedione 
 Insulin 

Data are n or means ± SEM, except where otherwise noted.

*

Diabetes duration median (range);

AER geometric mean (tolerance factor)

Close Modal

or Create an Account

Close Modal
Close Modal